The role of antibiotics and probiotics in pouchitis

Paolo Gionchetti, Andrea Calafiore, Donatella Riso, Giuseppina Liguori, Carlo Calabrese, Giulia Vitali, Silvio Laureti, Gilberto Poggioli, Massimo Campieri, Fernando Rizzello, Paolo Gionchetti, Andrea Calafiore, Donatella Riso, Giuseppina Liguori, Carlo Calabrese, Giulia Vitali, Silvio Laureti, Gilberto Poggioli, Massimo Campieri, Fernando Rizzello

Abstract

Pouchitis is a non-specific inflammation of the ileal reservoir and the most common complication of proctocolectomy with ileal pouch-anal anastomosis (IPAA) in patients with ulcerative colitis. Its frequency is related to the duration of the follow up, occurring in up to 50% of patients 10 years after IPAA in large series from major referral centers. Treatment of pouchitis is largely empirical and only small placebo-controlled trials have been conducted. The rationale for using probiotics and antibiotics in pouchitis is based on convincing evidence that implicates intestinal bacteria in the pathogenesis of this disease. Probiotics are living organisms, which, upon ingestion in certain numbers, exert health benefits beyond inherent basic nutrition. VSL#3, a highly concentrated cocktail of probiotics has been shown to be effective in the prevention of pouchitis onset and relapses. Antibiotics are the mainstay of treatment of pouchitis, and metronidazole and ciprofloxacin are the most common initial approaches, often with a rapid response. The use of antibiotics in pouchitis is largely justified although proper controlled trials have not been conducted.

Keywords: IBD; antibiotics; pouchitis; probiotics.

Conflict of interest statement

Conflict of Interest: None

Figures

Figure 1
Figure 1
Proposed treatment algorithm in pouchitis CD, Crohn’s disease; CMV, Cytomegalovirus; AZA/6MP, azathioprine/6-mercaptopurine, GCS, glucocorticosteroids

References

    1. Guarner F, Casellas F, Borruel N, et al. Role of microecology in chronic inflammatory bowel diseases. Eur J Clin Nutr. 2002;56:S34–S38.
    1. Neut C, Bulois P, Desreumaux P, et al. Changes in the bacterial flora of the neoterminal ileum after ileocolonic resection for Crohn's disease. Am J Gastroenterol. 2002;97:939–946.
    1. Manichanh C, Rigottier-Gois L, Bonnaud E, et al. Reduced diversity of faecal microbiota in Crohn's disease revealed by a metagenomic approach. Gut. 2006;55:205–211.
    1. Sokol H, Seksik P, Furet JP, et al. Low counts of fecalibacterium pausnitzii in colitis microbiota. Inflamm Bowel Dis. 2009;15:1183–1189.
    1. Sokol H, Pigneur B, Watterlot L, et al. Fecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn’ disease patients. PNAS. 2008;105:16731–16736.
    1. Duchmann R, Kaiser I, Hermann E, et al. Tolerance exist towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD) Clin Exp Immunol. 1995;102:445–447.
    1. Janowitz HD, Croen EC, Sachar DB. The role of the faecal stream in Crohn's disease: an historical and analytic perspective. Inflamm Bowel Dis. 1998;4:29–39.
    1. D’Haens GR, Geboes K, Peeters M, et al. Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology. 1998;114:771–774.
    1. Abdelrazeq AS, Kandiyil N, Botterill ID, et al. Predictors for acute and chronic pouchitis following restoration proctocolectomy for ulcerative colitis. Colorectal Dis. 2007;10:805–813.
    1. Sartor RB. Insights into the pathogenesis of inflammatory bowel disease provided by new rodent models of spontaneous colitis. Inflamm Bowel Dis. 1995;1:64–75.
    1. Campieri M, Gionchetti P. Probiotics in inflammatory bowel disease: new insight to pathogenesis or a possible therapeutic alternative? Gastroenterology. 1999;116:1246–1249.
    1. Metchnikoff E. London: William Heinemann; 1907. The Prolongation of Life: Optimistic Studies; pp. 161–183.
    1. Schaafsma G. State of the art concerning probiotic strains in milk products. IDF Nutr Newsl. 1996;5:23–24.
    1. Lee YK, Salminen S. The coming age of probiotics. Trends Food Sci Technol. 1995;6:241–245.
    1. Ng SC, Hart AL, Kamm MA, et al. Mechanism of action of probiotics: recent advances. Inflamm Bowel Dis. 2009;15:300–310.
    1. Pardi DS, D’Haens G, Shen B, Campbell S, Gionchetti P. Clinical guidelines for the management of pouchitis. Inflamm Bowel Dis. 2009;15:1424–1431.
    1. Ruseler-van-Embden JGH, Schouten WR, van Lieshout LMC. Pouchitis: result of microbial imbalance? Gut. 1994;35:658–664.
    1. Gionchetti P, Rizzello F, Venturi A, et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology. 2000;119:305–309.
    1. Mimura T, Rizzello F, Helwig U, et al. Once daily high dose probiotic therapy for maintaining remission in recurrent or refractory pouchitis. Gut. 2004;53:108–114.
    1. Ulisse S, Gionchetti P, D’Alò S, et al. Increased expression of cytokines, inducible nitric oxide synthase and matrix metalloproteinases in pouchitis: effects of probiotic treatment (VSL#3) Gastroenterology. 2001;96:2691–2699.
    1. Kuisma J, Mentula S, Kahri A, et al. Effect of Lactobacillus rhamnosus GG on ileal pouch inflammation and microbial flora. Aliment Pharmacol Ther. 2003;17:509–515.
    1. Shen B, Brzezinski A, Fazio VW, et al. Maintenance therapy with a probiotic in antibiotic-dependent pouchitis: experience in clinical practice. Aliment Pharmacol Ther. 2005;22:721–728.
    1. Gionchetti P, Rizzello F, Helvig U, et al. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind placebo controlled trial. Gastroenterology. 2003;124:1202–1209.
    1. Gionchetti P, Rizzello F, Morselli C, et al. High-dose probiotics for the treatment of active pouchitis. Dis Colon Rectum. 2007;50:2075–2082.
    1. Biancone L, Michetti P, Travis S, et al. European evidence-based Consensus in the management of ulcerative colitis: special situations. J Crohns Colitis. 2008;2:63–92.
    1. Sandborn WJ, Mc Leod, Jewell DP. Medical therapy for induction and maintenance of remission in pouchitis. A systematic review. Inflamm Bowel Dis. 1999;5:33–39.
    1. Hurst RD, Molinari M, Chung P, Rubin M, Michelassi F. Prospective study of the incidence, timing and treatment of pouchitis in 104 consecutive patients after restorative proctocolectomy. Arch Surg. 1996;131:497–502.
    1. Madden M, McIntyre A, Nicholls RJ. Double- blind cross-over trial of metronidazole versus placebo in chronic unremitting pouchitis. Dig Dis Sci. 1994;39:1193–1196.
    1. Shen B, Achkar JP, Lashner BA, et al. A randomized clinical trial of ciprofloxacin and metronidazole to treat acute pouchitis. Inflamm Bowel Dis. 2001;7:301–305.
    1. Gionchetti P, Rizzello F, Venturi A, et al. Antibiotic combination therapy in patients with chronic, treatment-resistant pouchitis. Aliment Pharmacol Ther. 1999;13:713–718.
    1. Mimura T, Rizzello F, Helwig U, et al. Four week open-label trial of metronidazole and ciprofloxacin for the treatment of recurrent or refractory pouchitis. Aliment Pharmacol Ther. 2002;16:909–917.
    1. Shen B, Fazio VW, Remzi FH, et al. Combined ciprofloxacin and tinidazole therapy in the treatment of chronic refractory pouchitis. Dis Colon Rectum. 2007;50:498–508.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe